Seal Software is set to be acquired by DocuSign, which invested $15m in the contact-management software provider last year.

Alphabet will exit credit management company Credit Karma in a $7.1bn acquisition by Intuit.

Valued at $13bn in November, SoftBank-backed food delivery platform developer DoorDash has confidentially filed for an initial public offering.

The Access Industries and Eli Lilly-backed genetic drug developer floated at the top of its range having increased the number of shares in the offering by 60%.

University of Pennsylvania-linked Passage Bio issued 4.6 million more shares than originally planned to raise $216m, up more than 70% on its $125m original target.

Takeda has bought UW spinout PvP Biologics, three years after acquiring an option to buy it in return for $35m in financing.

Nottingham-founded Excellerate Biosciences has been bought by Oxford's spinout OMass Therapeutics, which unveiled a series A extension last week.

Takeda has bought celiac disease therapy developer PvP Biologics, three years after acquiring an option to buy it in return for $35m in financing.

CRM app developer Vlocity had received $163m from investors including Salesforce itself as well as fellow corporates New York Life and Accenture.

Reports suggest Grab, which just raised $856m from strategic partners TIS and Mitsubishi UFJ Financial Group, is in talks to merge with rival Gojek in a $23bn deal.